23 completed, 11 unknown, 1 not yet recruiting. 35 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 35 | Completed 23, Unknown 11, Not yet recruiting 1 |
Follow Reference: new trials by email Literature Review of Reference trials Research Report on Reference
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-339 in Healthy Volunteers CKD-339, D311, D107 - Hypertension | Phase 1 | Not yet recruiting | Chong Kun Dang Pharmaceutical | 76 | 2026-08-20 | 2026-08-06 |
| Bioequivalence Study of ADC118 Tablets in Healthy Chinese Volunteers Under Fasting Conditions ACC118-Test, Reference - Human Immunodeficiency Virus (HIV) Infection | Phase 1 | Completed | Jiangsu Aidea Pharmaceutical Group Co., Ltd. | 48 | 2026-04-10 | 2026-08-10 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers CKD-383 0.25/12.5/1000mg, CKD-501, D745, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2025-10-30 | 2025-12-26 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers CKD-383 0.5/10/1000mg, CKD-501, D744, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2025-10-28 | 2025-12-26 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers CKD-383 0.5/25/1000mg, CKD-501, D745, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2025-10-24 | 2025-12-26 |
| Bioequivalence Study of Vortioxetine in 20 mg Coated Tablets in Healthy Subjects Under Fasting Conditions Reference, Test - Bioequivalance | Phase 1 | Completed | ADIUM | 20 | 2025-03-18 | 2026-06-03 |
| A Study to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UI059 and UIC202201 UI059, UIC202201 - Gastro-Intestinal Disorder | Phase 1 | Unknown | Korea United Pharm. Inc. | 66 | 2024-07-03 | 2024-05-01 |
| A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects UI059, UIC202201 - GERD | Phase 1 | Completed | Korea United Pharm. Inc. | 8 | 2023-10-08 | 2023-11-21 |
| A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices LY3437943, Test, Reference - Healthy | Phase 1 | Completed | Eli Lilly and Company | 57 | 2023-08-29 | 2024-03-29 |
| Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 500/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-08-22 | 2023-09-06 |
| Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 250/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-08-01 | 2023-08-31 |
| Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS 100/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-02-17 | 2023-03-09 |
| Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions CKD-386(4) F1, CKD-386(4) F2, D013, D326, D337 - Hypertension and Dyslipidemia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2022-09-23 | 2023-01-12 |
| Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fed Conditions CKD-387, D484 - Endocrine, Nutritional and Metabolic Diseases | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2022-09-19 | 2024-05-03 |
| Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fasting Conditions CKD-387, D484 - Endocrine, Nutritional and Metabolic Diseases | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 37 | 2022-09-16 | 2024-05-03 |
| Clinical Trial to Evaluate the Pharmacokinetic Characteristics of DW5221 and DW5221-R DW5221, DW5221-R - Apetite Stimulants | Phase 1 | Completed | Daewon Pharmaceutical Co., Ltd. | 54 | 2022-07-01 | 2023-11-28 |
| A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals, FLOVENT DISKUS - Asthma, Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 36 | 2022-05-11 | 2022-05-31 |
| Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects D418 Tab., CKD-388 Tab. - Chronic Hepatitis b | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 65 | 2022-01-14 | 2022-09-28 |
| Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Test, Reference - Bioequivalence, Asthma | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 18 | 2021-10-01 | 2021-10-20 |
| A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals, FLOVENT DISKUS - Asthma, Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 50 | 2021-08-13 | 2021-08-26 |
Showing 20 of 35. Sign in to see all of them.
Asthma (4) · Diabetes Mellitus, Type 2 (3) · Arthritis, Rheumatoid (2) · Back Pain (2) · Cardiovascular Diseases (2) · Gastroesophageal Reflux (2) · Hepatitis B, Chronic (2) · Hypertension (2) · Metabolic Diseases (2) · Osteoarthritis (2) · Acquired Immunodeficiency Syndrome (1) · COVID-19 (1) · Digestive System Diseases (1) · Dyslipidemias (1) · Hepatitis B (1)
Chong Kun Dang Pharmaceutical (12) · Respirent Pharmaceuticals Co Ltd. (8) · Daewon Pharmaceutical Co., Ltd. (3) · Korea United Pharm. Inc. (3) · ADIUM (1) · Dong-A ST Co., Ltd. (1) · Eli Lilly and Company (1) · Jiangsu Aidea Pharmaceutical Group Co., Ltd. (1) · Kocak Farma (1) · Mepha Ltd. (1) · Reckitt Benckiser Healthcare (UK) Limited (1) · Riverside Pharmacueticals Corporation (1) · Sun Pharma Advanced Research Company Limited (1)
South Korea (19) · Greece (8) · Canada (2) · China (1) · Germany (1) · Mexico (1) · Turkey (Türkiye) (1) · United States (1)
Chrysoula Doxani, MD, MSc, PhD (5) · Chrysoula Doxani, Dr. (1) · Frank Donath, MD (1) · Ioannis Stefanidis, Professor (1) · Jaewoo Kim (1) · Jaewoo Kim, M.D. (1) · Jang Hee Hong (1) · Min Kyu Park, Dr (1) · Minkyu Park, Dr (1) · Minkyu Park, MD, PhD (1) · Muradiye Nacak, MD,PhD (1) · Robert Adams, MBBS (1) · Stephane Lamouche, PhD (1)